Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 16/20 | 0.65 |
| ▸ | F10 | P00742 | 8/20 | 0.65 |
| ▸ | PLG | P00747 | 6/20 | 0.65 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.65 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.65 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.65 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7415072 | 0.86 | F2 (0.48) | F2F10PLGPRSS1PRSS2 | |
| SCHEMBL4448766 | 0.82 | F2 (0.59) | F2F10PLGPRSS1PRSS2 | |
| SCHEMBL8031432 | 0.81 | F2 (0.79) | F2F10PLGPRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL8026423 | 0.80 | F2 (0.78) | F2F10PLGPRSS1PRSS2 | |
| SCHEMBL7968288 | 0.79 | F2 (1.00) | F2F10PLGPRSS1PRSS2 | |
| SCHEMBL4451561 | 0.79 | F2 (1.00) | F2F10PLGPRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL7410692 | 0.78 | F2 (0.98) | F2F10PLGPRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL7982145 | 0.78 | F2 (0.98) | F2F10PLGPRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL7460376 | 0.78 | F2 (0.97) | F2F10PLGPRSS1PRSS2 | |
| Hydrochloric Acid SCHEMBL7977977 | 0.77 | F2 (0.68) | F2F10PLGPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1095025-B1 | BENZIMIDAZOLES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-12-11 | — | — | EP | claimed |
| US-6248770-B1 | CARDIOVASCULAR DISORDERS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-06-19 | — | — | US | claimed |
| US-20090022686-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2009-01-22 | — | — | US | disclosed |
| EP-1517687-B1 | MEDICAMENT FOR THE TREATMENT OF THE SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOEHRINGER INGELHEIM PHARMA (DE) | 2007-06-20 | — | — | EP | disclosed |
| US-20040023975-A1 | Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-02-05 | — | — | US | disclosed |
| EP-1095025-B1 | BENZIMIDAZOLES, PRODUCTION THEREOF AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM PHARMA (DE) | 2002-12-11 | — | — | EP | disclosed |
| US-6248770-B1 | CARDIOVASCULAR DISORDERS | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2001-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040023975-A1 | Pharmaceutical compositions for the treatment of systemic inflammatory response syndrome | IL5, TSLP, TLR5 | F2 214/4885F10 1136/4885PLG 453/4885 |
| US-20090022686-A1 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | IL5, TSLP, TLR5 | F2 214/4885F10 1136/4885PLG 453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.